June 26th 2018
Treatments for respiratory diseases represent an enormous, unmet medical need with limited therapies currently approved for use. Despite many compounds demonstrating beneficial effects in animals models, very few translate into successful therapies. To improve translational efficacy of respiratory animal models, researchers are calling for the development of new druggable targets, better biomarkers and the use of more clinically relevant endpoints in preclinical animal studies. This presentation will describe a novel technology platform that allows for non-invasive real-time monitoring of lung function in preclinical studies of respiratory disease and will present several use cases demonstrating how automated longitudinal monitoring provides insight into disease biology in animal models of Idiopathic Pulmonary Fibrosis (IPF) and Pneumonia.